Benjamin Bonavida
About
In The Last Decade
Benjamin Bonavida
456 papers receiving 15.8k citations
Hit Papers
Peers
Comparison fields: 5 of 153
- Molecular Biology 7.4k
- Immunology 5.7k
- Oncology 4.5k
- Cancer Research 2.5k
- Pathology and Forensic Medicine 2.4k
Countries citing papers authored by Benjamin Bonavida
This map shows the geographic impact of Benjamin Bonavida's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Benjamin Bonavida with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Benjamin Bonavida more than expected).
Fields of papers citing papers by Benjamin Bonavida
This network shows the impact of papers produced by Benjamin Bonavida. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Benjamin Bonavida. The network helps show where Benjamin Bonavida may publish in the future.
Co-authorship network of co-authors of Benjamin Bonavida
This figure shows the co-authorship network connecting the top 25 collaborators of Benjamin Bonavida. A scholar is included among the top collaborators of Benjamin Bonavida based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Benjamin Bonavida. Benjamin Bonavida is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 6 | |
| 2 | 5 | |
| 3 | 30 | |
| 4 | 84 | |
| 5 | 78 | |
| 6 | 47 | |
| 7 | 3 | |
| 8 | Sensitization of B-NHL resistant tumor cells overexpressing Bcl-xL to TRAIL-induced apoptosis by the novel proteasome inhibitor Salinosporamide A (NPI-0052) | 1 |
| 9 | Role of plasma membrane fluidity alterations in tumor cell sensitization to apoptosis-inducing stimuli: Therapeutic implications | 4 |
| 10 | Characteristics of rituximab-resistant B-NHL clones: deficiencies in rituximab-mediated changes in lipid raft microdomains and cell signaling | 4 |
| 11 | New Targets identified for therapeutic intervention in the reversal of rituximab and drug resistant AIDS-B-NHL. | 2 |
| 12 | Rituximab sensitizes resistant B-NHL cell lines to the proteasome inhibitor NPI-0052-induced apoptosis. | 1 |
| 13 | Overexpression of inhibitor of apoptosis protein XIAP in human prostate cancer | 1 |
| 14 | 39 | |
| 15 | 16 | |
| 16 | 44 | |
| 17 | Tumor necrosis factor : structure-function relationship and clinical application | 28 |
| 18 | Tumor necrosis factor : structure, mechanism of action, role in disease and therapy | 26 |
| 19 | Lysis of NK target cells by soluble cytotoxic factor(s) and inhibition by a xenoantiserum directed against cytotoxic cells. | 2 |
| 20 | Studies on the induction and expression of T cell-mediated immunity. IV. Non-overlapping populations of alloimmune cytotoxic lymphocytes with specificity for tumor-associated antigens and transplantation antigens. | 14 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.